Solana (NASDAQ:HSDT) vs. NeuroPace (NASDAQ:NPCE) Critical Review

Solana (NASDAQ:HSDT) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Institutional and Insider Ownership

18.6% of Solana shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 14.4% of Solana shares are held by insiders. Comparatively, 20.5% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Solana and NeuroPace”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02 million	19.33	-$40.89 million	($490.68)	0.00
NeuroPace	$99.99 million	5.80	-$21.47 million	($0.66)	-25.86

NeuroPace has higher revenue and earnings than Solana. NeuroPace is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Solana has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Solana and NeuroPace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	1	1	2.50
NeuroPace	1	1	4	2	2.88

Solana presently has a consensus target price of $3.50, indicating a potential upside of 65.09%. NeuroPace has a consensus target price of $18.67, indicating a potential upside of 9.35%. Given Solana’s higher possible upside, analysts plainly believe Solana is more favorable than NeuroPace.

Profitability

This table compares Solana and NeuroPace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-679.54%	-104.96%	-20.67%
NeuroPace	-21.47%	-105.67%	-20.01%

Summary

NeuroPace beats Solana on 11 of the 15 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.